TB-500 research: what the literature shows
A well-characterized molecular mechanism, a substantial preclinical literature, and a still-developing human clinical evidence base.
TL;DR
- The TB-500 / Thymosin Beta-4 research base spans cell biology (well-characterized actin mechanism), preclinical animal studies (substantial across multiple tissue types), and human clinical research (limited and mostly focused on specific indications like dermal wounds and ophthalmic conditions).
- The asymmetry between preclinical breadth and human clinical depth is similar to the BPC-157 evidence pattern, and is one of the central reasons TB-500 is currently Category 2.
- TB-500 is not currently available through Halftime Health.
What it is
The published research on Thymosin Beta-4 spans multiple decades and includes work in cell biology, animal models, and a smaller set of human clinical investigations. PubMed indexes hundreds of peer-reviewed papers across this range, with substantial concentrations in cardiac, musculoskeletal, dermal, and ophthalmic contexts.
Where the evidence is strong
The strongest part of the evidence base is the molecular mechanism. Actin sequestration through Thymosin Beta-4 binding has been characterized in considerable biochemical detail and is well established as a fundamental cellular process (Goldstein et al., Annals of the New York Academy of Sciences, 2012). The preclinical animal literature is also substantial and reasonably consistent across multiple tissue types — cardiac injury, dermal wound healing, musculoskeletal injury, and ophthalmic models all show effects on cell migration and tissue remodeling that are mechanistically consistent with the actin story.
Some specific human research has been conducted: topical Thymosin Beta-4 formulations have been investigated for dermal wound healing, and ophthalmic formulations have been studied for corneal indications (Crockford et al., Annals of the New York Academy of Sciences, 2010).
Where the evidence is limited
Robust randomized human clinical trials of TB-500 specifically — for the indications most discussed in peptide-protocol contexts (tendon repair, muscle recovery, athletic recovery) — are limited. Standardized human pharmacokinetic data is sparse. And much of the preclinical literature uses full-length Thymosin Beta-4 rather than the TB-500 synthetic fragment, which adds a translation layer when applying the research base specifically to TB-500 in human protocol contexts.
Who asks about it
People come to this topic when they are weighing whether the popular descriptions of TB-500 are supported by the underlying research. The honest read is: the molecular mechanism is well established, the preclinical breadth is real, and the human clinical trial base for the most-discussed protocol indications is not yet at the standard required for compounding eligibility.
What the research says
The most useful single-sentence summary of the TB-500 literature is this: a well-characterized molecular biology, a broad preclinical literature, and a thin human clinical literature for the indications most discussed in protocol contexts. That asymmetry is what the FDA's Category 2 placement reflects.
What to know before considering it
TB-500 is a Category 2 peptide as of April 2026 and is not available through Halftime Health or any licensed 503A compounding pharmacy. The reclassification process may eventually change that, but the research landscape and the regulatory status are aligned: both reflect the human clinical evidence gap.
The Halftime POV
The TB-500 research is genuinely interesting at the molecular and preclinical level — actin regulation is one of the better-characterized peptide mechanisms in the literature. Honest description of where the human evidence base stands today is what good educational content looks like, and it is the position the regulatory framework reflects.
Related reading:
- TB-500: what Thymosin Beta-4 is and why it matters
- How TB-500 works: actin regulation and tissue signaling
- TB-500 for tissue repair: what the research shows
FAQ
Q: Are there human trials of TB-500? A: Some Thymosin Beta-4 human research has been conducted in specific clinical contexts — including topical formulations for dermal wounds and ophthalmic indications — but robust randomized human trials of TB-500 specifically for the indications most discussed online (tendon repair, muscle recovery) are limited. The thin human evidence base is one factor in TB-500's current FDA Category 2 classification.
Q: Where is the TB-500 evidence strongest? A: The strongest part of the TB-500 evidence base is the molecular mechanism — actin sequestration is well characterized at the cellular and biochemical level. The preclinical animal literature is also substantial, particularly in cardiac injury and dermal wound healing models.
Q: What are the main limitations of TB-500 research? A: Limitations include limited robust human clinical trials for the indications most discussed in protocol contexts, lack of standardized human pharmacokinetic data, and the distinction between full-length Thymosin Beta-4 (used in much of the preclinical research) and the synthetic TB-500 fragment (used in protocol contexts). These factors informed the FDA's 2023 Category 2 placement.
Disclaimer
As of April 2026, TB-500 is classified by the FDA as a Category 2 peptide and is not available through licensed 503A compounding pharmacies. A February 2026 HHS announcement proposed returning TB-500 to Category 1 pending formal FDA Federal Register notice. Halftime Health does not currently offer TB-500. This article is educational only and is not medical advice.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Annals of the New York Academy of Sciences, 2012.
- Crockford D, et al. Thymosin β4: structure, function, and biological properties. Annals of the New York Academy of Sciences, 2010.
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Are there human trials of TB-500?
Some Thymosin Beta-4 human research has been conducted in specific clinical contexts — including topical formulations for dermal wounds and ophthalmic indications — but robust randomized human trials of TB-500 specifically for the indications most discussed online (tendon repair, muscle recovery) are limited. The thin human evidence base is one factor in TB-500's current FDA Category 2 classification.
Where is the TB-500 evidence strongest?
The strongest part of the TB-500 evidence base is the molecular mechanism — actin sequestration is well characterized at the cellular and biochemical level. The preclinical animal literature is also substantial, particularly in cardiac injury and dermal wound healing models.
What are the main limitations of TB-500 research?
Limitations include limited robust human clinical trials for the indications most discussed in protocol contexts, lack of standardized human pharmacokinetic data, and the distinction between full-length Thymosin Beta-4 (used in much of the preclinical research) and the synthetic TB-500 fragment (used in protocol contexts). These factors informed the FDA's 2023 Category 2 placement.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.